More recent study on Golimumab—a human IgG1-κ monoclonal antibody specific for human TNF-α, administered to 84 pediatric and adult patients with recent-onset T1D (treatment: 56 patients, placebo: 28 patients) at 52 weeks—showed significant preservation of 4-hour AUC C-peptide (P < .001) and lower insulin use (P = .001; Quattrin et al, 2020). This evidence concerns the gene INS and type 1 diabetes mellitus.